

## OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20<sup>th</sup> Congress of ECCO

NANTES, France - January 28 2025, – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), shares details of the three scientific abstracts on its anti-IL-Receptor (IL-7R) Lusvertikimab, which is in clinical development for ulcerative colitis. These abstracts will be presented in Oral Presentation, Digital Oral Presentation and Poster Presentation at the upcoming 20<sup>th</sup> Congress of ECCO (European Crohn’s and Colitis Organization) to be held February 19-22, 2025, in Berlin (Germany).

**Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics**, comments: *“With three abstracts accepted for presentation at ECCO 2025, we look forward to sharing new preclinical and clinical efficacy data on Lusvertikimab with the world’s leading specialists in Inflammatory Bowel Diseases (IBD).”*

**Presentation Details:**

Oral presentation			
Title	Presenter	Session	Date and time
<b><u>OP36 - "LUSVERTIKIMAB, A FIRST-IN-CLASS IL7 RECEPTOR ANTAGONIST, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY "</u></b>	Arnaud Bourreille	Session name: Sustainability in IBD and beyond Session 10: Hot topics in IBD Session hall: Plenary Hall / Hall B	Session date: February 20, 2025 Session time: 08:30 -10:50 Presentation time: 10:10 - 10:20
<i>Selected amongst the Top 10 oral abstracts for 20th Congress of European Crohn’s and Colitis Organization (ECCO) Highlights.</i>			

Digital oral presentation			
Title	Presenter	Session	Date and time
<b><u>DOP031 - "ANTI-IL-7 RECEPTOR PLUS ANTI-IL12/23 COMBINATION INDUCES COMPLETE HISTOLOGICAL NORMALIZATION IN CHRONIC COLITIS "</u></b>	Nicolas Poirier	Session name: DOP Session 4: Novel targets in IBD Session hall: A5	Session date: February 20, 2025 Session time: 17:45 - 18:45 Presentation time: 18:03 - 18:09

Poster presentation		
Title	Presenter	Session Date and time
<b>PO916 – “LUSVERTIKIMAB IS EFFICACIOUS IN SEVERE ULCERATIVE COLITIS (UC) PATIENTS WITH HIGH FECAL CALPROTECTIN (FCP): RESULTS FROM THE COTIKIS STUDY”</b>	Walter Reinish	Poster sessions: February 20, 2025, 10:30 to 18:00 February 21, 2025, 08:00 to 18:00 February 22, 2025, 09:00 to 13:00 Guided poster session: February 21, 2025, 12:40-13:40

### ABOUT OSE IMMUNOTHERAPEUTICS

OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.

Additional information about OSE Immunotherapeutics assets is available on the Company’s website: [www.ose-immuno.com](http://www.ose-immuno.com). Click and follow us on X and LinkedIn



### Contacts

**Fiona Olivier**

[fiona.olivier@ose-immuno.com](mailto:fiona.olivier@ose-immuno.com)

**Sylvie Détry**

[sylvie.detry@ose-immuno.com](mailto:sylvie.detry@ose-immuno.com)

**French Media Contact**

**FP2COM**

Florence Portejoie

[fportejoie@fp2com.fr](mailto:fportejoie@fp2com.fr)

+33 6 07 768 283

**U.S. Media Contact**

Rooney Partners LLC

Kate Barrette

[kbarrette@rooneypartners.com](mailto:kbarrette@rooneypartners.com)

+1 212 223 0561

### Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.